Status:
RECRUITING
SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Lead Sponsor:
The University of Hong Kong
Conditions:
Lupus Nephritis
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). Although the stan...
Detailed Description
Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). The standard-of-c...
Eligibility Criteria
Inclusion
- Patients with biopsy-proven Class III or IV or V LN according to the ISN/RPS 2003 classification
- Patients with CKD (eGFR 15-60mL/min)
- Patients in quiescent disease (defined as SLEDAI score \<4 with no points in the renal domain)
- Patients on a stable dose of prednisolone (PRED 5-7.5 mg/D) alone or in combination with MMF (\<=1.5 g/D) or AZA (\<=150 mg/D) in the past 3 months
Exclusion
- Patients with biopsy-proven glomerulonephritis other than LN or hereditary kidney diseases
- Patients with type 1 diabetes mellitus (DM)
- Patients with stage 5 CKD or ESKD on renal replacement therapy
- Patients with frequent urinary tract infections
- Patients with history of ketoacidosis
Key Trial Info
Start Date :
January 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06155604
Start Date
January 4 2023
End Date
December 31 2026
Last Update
December 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong